Allogeneic HCT in AML patients in second remission

In this study of patients with acute myeloid leukemia (AML), 1,271 of 3,919 patients age 16 to 49 years who did not receive a transplant in first complete remission (CR1) relapsed. The percentage of these relapsed patients able to achieve CR2 was 55%, which varied by risk group: favorable (82%), intermediate (54%), adverse (27%), and unknown (53%). Five-year survivals of these patients were 32%, 17%, 7%, and 23%, respectively. Of these relapsed patients, 19% are alive beyond 5 years. The authors conclude that “successful salvage treatment of patients who do not undergo transplantation in CR1 and relapse can be achieved in 19% of patients, which is improved by a transplant except in favorable risk disease.”

Burnett AK, et al. J Clin Oncol

Two editorials discussing these results: 1. Dr. Richard Stone, 2. Dr. Charles Schiffer.